Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview
November 12, 2020 07:15 ET
|
Protara Therapeutics
- On Track to Complete GMP Batch Runs in Mid-2021 to Confirm Comparability Between TARA-002 and OK-432 -- Expect to Initiate Phase 1 Trial for TARA-002 in Patients with Non-Muscle Invasive Bladder...
Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
November 11, 2020 07:00 ET
|
Protara Therapeutics
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2020 07:00 ET
|
Protara Therapeutics
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
September 22, 2020 08:13 ET
|
Protara Therapeutics
NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
September 21, 2020 16:01 ET
|
Protara Therapeutics
NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications
September 08, 2020 07:00 ET
|
Protara Therapeutics
- Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs - - Reaches Alignment with FDA on Development Path Forward for TARA-002 in...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2020 17:49 ET
|
Protara Therapeutics
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases...
Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview
August 03, 2020 07:00 ET
|
Protara Therapeutics
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs,...
Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations
July 28, 2020 07:00 ET
|
Protara Therapeutics
NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs,...
Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors
July 24, 2020 07:00 ET
|
Protara Therapeutics
NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs,...